全球肺炎治疗市场分析和市场规模 – 趋势、预测和关键见解

全球肺炎治疗市场 - 行业概况

全球肺炎治疗市场预计将大幅增长，这主要归因于全球肺炎发病率的上升，对医疗基础设施较差的中低收入国家的影响尤其严重。根据世界卫生组织的数据，肺炎仍然是弱势群体，特别是五岁以下儿童死亡的主要原因。2019 年，肺炎导致 740180 名 5 岁以下儿童死亡，占 5 岁以下儿童死亡总数的 14%，这凸显了对更有效的治疗和预防措施的迫切需求。抗生素耐药性的上升，特别是针对肺炎链球菌等常见感染的耐药性，是推动对创新药物（如下一代抗生素、改良疫苗和支持性护理方法）需求的主要驱动因素。

Data Bridge 市场研究市场报告提供了最新发展、市场份额、基于细分和区域分析的市场趋势、市场参与者的影响、新兴收入领域机会分析、市场法规变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地理扩展、市场技术创新的详细信息。要获取有关市场的更多信息，请联系 Data Bridge 市场研究的专家分析师团队。我们的团队将帮助您做出明智的市场决策，以实现业务增长。

全球肺炎治疗市场规模

The global pneumonia therapeutics market is also witnessing increased investment in research and development to combat the growing threat of multidrug-resistant strains of Streptococcus pneumonia. Furthermore, the introduction of newer vaccines, such as the Pneumococcal Conjugate Vaccine (PCV), and advancements in antiviral medications are playing a critical role in mitigating the global pneumonia therapeutics market growth. As a result, Databridge Market Research dived into comprehensively analyzing the market and unveiled that the Global Pneumonia Therapeutics Market is increasing at a CAGR of 8.10%. Our detailed analysis forecasts that the market is valued at USD 2.51 billion in 2023 and is expected to grow upto USD 4.68 billion by 2031. Our meticulously created report, developed through comprehensive research and analytics, is a distinguished paper that unveils eye-opening data about the market.

Global Pneumonia Therapeutics Market Dynamics

Global Pneumonia Therapeutics Market Growth Drivers

Increase in pneumonia Cases

The rising prevalence of pneumonia, particularly among vulnerable populations such as children under five and the elderly, is a primary driver of the global pneumonia therapeutics market. According to the World Health Organization (WHO), pneumonia causes 14% of all child fatalities under the age of five, killing roughly 740,180 children each year. Such worrisome trend emphasizes the critical need for improved treatments and prevention strategies.

Antibiotic Resistance

Centers for Disease Control and Prevention (CDC) reports that in the United States alone, about 30% of Streptococcus pneumoniae infections are resistant to one or more clinically relevant antibiotics. Antibiotic resistance, particularly in strains for instance, Streptococcus pneumoniae, is a critical challenge driving the need for new antibiotics and combination therapies in the pneumonia therapeutics market. Consequently, the urgent need to combat such resistant strains has spurred significant investment in the research and development of novel antibiotics, as well as combination therapies

Global Pneumonia Therapeutics Market growth Opportunities

Growing Clinical Trials

Growing number of on-going clinical trials for the development of drug molecules will have a major impact on the market progression. For instance, According to WHO, in 2022 global clinical trial activity remained strong despite the COVID-19 pandemic. Non-COVID trial activity increased by 8% from 2019 to 2022.  The expansion of clinical research not only accelerates the development of breakthrough treatments but also stimulates investment and fosters collaboration across the healthcare sector, thereby propelling the overall growth of the pneumonia therapeutics market.

Government and healthcare initiatives

Government and healthcare initiatives, including expanded immunization programs and improved healthcare access, significantly support the growth of the global pneumonia therapeutics market. for instance, U.S. Healthy People 2030 objectives, aim to improve access to preventive and therapeutic services for pneumonia, further enhancing market growth.

Global Pneumonia Therapeutics Market Growth Challenges

High Cost of Therapy

The high cost of advanced pneumonia therapies, such as novel antibiotics and biologics, presents a significant challenge to market growth. For instance, the development of new antibiotics can cost upwards of $1.5 billion, considering the extensive research, clinical trials, and regulatory processes involved. Similarly, biologics, which include monoclonal antibodies and other specialized treatments, can have development costs exceeding $2 billion. Financial barrier's limits the ability of these regions to procure and administer advanced treatments, impacting overall pneumonia management and hindering market expansion.

Lack of technical skills.

Limited healthcare infrastructure in low- and middle-income regions severely impacts pneumonia management and market growth. For instance, According to WHO the share of health in government spending increased over the past two decades in upper-middle and high income countries, stagnated in lower-middle income countries and declined in low income countries between 2000 and 2011. Consequently, the inability to provide timely and appropriate care in lower-middle income countries not only affects patient outcomes but also hinders the overall growth of the pneumonia therapeutics market.

Global Pneumonia Therapeutics Market Growth Restraints

Regulatory and market approval hurdles

The approval process for new therapies is both rigorous and time-consuming, requiring extensive Navigating regulatory and market clearance hurdles is a major problem in the pneumonia therapeutics market, frequently resulting in delays and increased costs for novel medicines. For instance, the antibiotic Ceftaroline required a lengthy approval process from the United States Food and Drug Administration (FDA) due to rigorous evaluation of clinical trial data and manufacturing practices. Such lengthy and costly approval processes not only add to pharmaceutical companies' financial burdens, but also delay the introduction of potentially life-saving pneumonia medicines to the market, impacting patient access and overall market growth.

Global Pneumonia Therapeutics Market Scope and Trends

• In a recent study published in the American Society for Microbiology, researchers created a unique rabbit infection model to explore meropenem's resistance development potential and antibacterial activity. Meropenem is an antibacterial medication that is considered the current gold standard in hospital-acquired pneumonia (HAP) therapy. The work contributes to the identification of Regimen Intensification and Combination Therapy as potential mitigation strategies against the formation of multiple antimicrobial resistance (AMR) bacterial strains.
• Orchid Pharma has acquired license from the Drugs Controller General of India (DCGI) to manufacture and distribute Enmetazobactam, an innovative New Chemical Entity Active Pharmaceutical Ingredient (API). Enmetazobactam will be used to treat complicated urinary tract infections (cUTI), such as acute pyelonephritis, hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), and bacteremia.
• Antiviral drugs are essential for treating pneumonia caused by viral infections such as influenza and SARS-CoV-2. For instance, newer antiviral medications such as Paxlovid and Molnupiravir have been developed to combat SARS-CoV-2 and are being refined to enhance their efficacy against evolving variants.

Global Pneumonia Therapeutics Market Regional Analysis – Market Trends

Key Insights

• North America dominates the market due to its advanced healthcare systems and high levels of public awareness about pneumonia prevention and treatment. The United States, with its well-established healthcare infrastructure and significant investment in research and development, leads in the adoption of new pneumonia therapies.
• Asia-Pacific is predicted to rise the fastest due to rising healthcare spending, increased awareness, and improved access to pneumonia treatments. Countries such as China and India are investing in healthcare facilities and vaccination programs to combat the high prevalence of pneumonia, particularly among youngsters. The expanding middle class and improved healthcare services in the region are significant drivers of market expansion.
• 中东和非洲国家医疗资源和基础设施匮乏，这对肺炎管理产生了影响。尽管存在这些障碍，但在国际援助和政府举措的推动下，人们越来越重视改善医疗体系，提高疫苗和治疗的可及性。
• 欧洲拥有强大的医疗保健系统和广泛的创新疗法，在肺炎治疗市场占有相当大的份额。欧盟强调通过预防措施（包括全面的免疫计划和出色的肺炎管理策略）改善公共卫生，从而促进了市场的增长。

全球肺炎治疗市场领先企业

• 阿斯利康（英国）
• 礼来（美国）
• 霍夫曼-罗氏有限公司（瑞士）
• Mylan NV（美国）
• Teva Pharmaceutical Industries Ltd.（以色列）
• 赛诺菲（法国）
• 诺华公司（瑞士）
• 太阳制药工业有限公司 (印度)
• Aurobindo Pharma（印度）
• 鲁冰花（印度）
• 默克公司（美国）
• 辉瑞公司（美国）
• 葛兰素史克公司 (英国)
• Hikma Pharmaceuticals PLC（英国）
• Cipla Inc.（印度）

全球肺炎治疗市场最新发展

• 2024年5月，再鼎医药与Innoviva Specialty Therapeutics在中国获得国家药品监督管理局批准XACDURO（舒巴坦-杜洛巴坦或SUL-DUR），用于治疗由鲍曼不动杆菌-乙酸钙复合物引起的医院获得性肺炎和呼吸机相关性肺炎。
• 2023 年 9 月，Phaxiam Therapeutics SA 启动了一项新的临床前研究项目，针对肺炎克雷伯菌，这是一种引起严重感染并以其强大的抗生素耐药性而闻名的细菌。
• 2023年5月，美国食品药品监督管理局批准了Innoviva Specialty Therapeutics生产的新药Xacduro，用于治疗由难以治疗的细菌引起的医院内获得性肺炎。
• 2023年11月 创新药物倡议的COMBINE（预防和治疗MDR细菌感染的合作）倡议正在创建标准化的体内肺炎模型，以测试小分子抗生素。

SKU-56739